RTX is developing a platform of bifunctional redox-based small molecules formed from the covalent linkage of an organic nitrovasodilatordomain that donates nitric oxide and a multifunctional redox catalytic domain. These agents remove toxic reactive oxygen species and deliver NO without the confounding effect of producing the potent toxin peroxynitrite via the diffusion-limited reaction of nitric oxide and superoxide.
Andrew L. Salzman, M.D. (Chairman and Founder) is a physician, scientist, inventor, and biomedical entrepreneur. Dr. Salzman received his undergraduate training at Yale College, followed by medical education at Harvard Medical School, and fellowships in critical care and infectious disease at the Weizmann Institute of Science, Children's Hospital (Boston, MA), the Massachusetts General Hospital, University of Massachusetts, and Beth Israel Hospital (Boston, MA).
RTX pursues its product discovery work primarily utilizing classic rational-based medicinal chemistry approaches, supported by computational algorithms based upon crystallographic data. The company operates an efficient in-house iteractive drug discovery process, whereby hits are subjected to rapid validation by in vitro cell culture testing with quick follow on in vivo confirmation in rodent and large animal disease models. This approach has consistently yielded highly potent and innovative pharmaceutical candidates.